Liver Disease Management

Assessment of Hepatic Functional Reserve

• The Child-Pugh score is a fundamental tool for assessing hepatic functional reserve in patients with chronic liver disease, providing critical prognostic information that guides treatment decisions, particularly regarding surgical interventions, transplantation candidacy, and overall management strategies, as recommended by the National Comprehensive Cancer Network 1
• The Model for End-Stage Liver Disease (MELD) score is a widely used scoring system to predict short-term (3-month) mortality in patients with end-stage liver disease, calculated using three objective laboratory parameters: serum bilirubin, serum creatinine, and International Normalized Ratio (INR), with a formula: MELD Score = 3.78 × log(bilirubin in mg/dL) + 11.2 × log(INR) + 9.6 × log(creatinine mg/dL) + 6.4, and correlates directly with the risk of mortality, with higher scores indicating increased risk 2, 3, 4, 5, 6, 7
• The following mortality risks are associated with MELD scores:

• The Child-Turcotte-Pugh (CTP) score is another well-established scoring system that includes 5 parameters: 3 laboratory parameters (albumin, bilirubin, and prothrombin time/INR) and 2 clinical parameters (encephalopathy and ascites), useful for classifying severity of cirrhosis and predicting long-term outcomes (1-5 years), with a classification that includes Class A (5-6 points, compensated cirrhosis), Class B (7-9 points), and Class C (10-15 points, decompensated cirrhosis) 8, 9, 3, 1

Indications and Contraindications for Transplantation

• Active extrahepatic malignancy (except for neuroendocrine tumors) and cholangiocarcinoma (unless part of a novel management strategy) are contraindications for transplantation, and severe comorbidities, including advanced cardiac disease, severe pulmonary disease, and advanced neurological disease, are contraindications for transplantation, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 2, 10, 11
• Patients with hepatitis B must be HBV DNA negative before transplantation, which can be achieved with antiviral treatment, and patients with hepatitis C and advanced cirrhosis with complications, as well as those with advanced alcoholic liver disease with poor prognosis, are indications for transplantation 10, 7, 10
• Small HCC complicating cirrhosis is recommended for transplantation, and size limitations for HCC tumors (>5 cm or more than three in number) require novel management strategies, as suggested by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 10

Monitoring and Evaluation

• Assess liver function with laboratory tests and calculate both CTP and MELD scores every 6 months in stable patients, and consider liver transplantation evaluation when MELD score ≥15, major complications of cirrhosis occur (ascites, variceal bleeding, hepatic encephalopathy), or CTP class C, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 3, 4
• Regular monitoring of the MELD score is essential, as it can change over time, and reevaluation is recommended every 3-6 months in stable patients, with more frequent monitoring (every 1-3 months) if there are signs of clinical deterioration, as suggested by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 3, 12

Post-Transplant Outcomes

• MELD scores correlate inversely with post-transplant survival, and very high MELD scores (>25) are associated with poorer post-transplant outcomes, with maximum impact during the first year, and female patients may have worse outcomes than males with the same MELD score, particularly in the creatinine-dominant subtype, as noted by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 4, 13
• The benefits of liver transplantation typically emerge when MELD exceeds 14, and a MELD score ≥15 is the minimum recommended threshold for including patients with end-stage liver disease on the transplant waiting list, corresponding to a 5-year transplant benefit of 12 months of life gain, as recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver 3, 4, 2